RP:TSX.V; REPCF:OTCQB

RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Companyís product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCelís innovative technology, utilizing cell populations isolated from a patientís healthy hair follicles. The Company has also developed a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications.
RP:TSX.V REPCF:OTCQB

Expert Comments:

Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss.
read more >
SmallCap Network (4/4/17)
"Replicel Life Sciences Inc. announced statistically and clinically significant positive data from the interim analysis of its phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin, and the markets are loving the news. . .the study observed the impact of the injection on ten different biomarkers that, in peer-reviewed medical literature, are highly correlated with skin aging and chronically sun-damaged skin. . .gene expression markers, such as tissue inhibitor of metalloproteinases, showed significant changes expected to correlate with increased collagen fibers. Increased collagen production, and reduced collagen degradation, is associated with fewer wrinkles and the repair of sun-damaged skin."

Douglas Loe, Echelon Wealth Partners (4/4/17)
"RepliCel Life Sciences Inc. reported interim data this morning from its 17-patient Germany-based Phase I trial evaluating impact from its autologous non-bulbar dermal sheath cell (NBDS)-based therapy RCS-01 on biochemical markers of skin rejuvenation. . .clear evidence that RCS-01 up-regulates biochemical pathways that are known to be relevant to skin rejuvenation, as study design intended. . .the trial absolutely met its primary endpoint of demonstrating safety in patients, with no serious adverse events reported at the time of the trial. . .we continue to maintain our Price Target of $3.50."

Etienne Moshevich, Alphastox.com (4/4/17)
"RepliCel Life Sciences Inc. is finally in a position to drive substantial growth for shareholders by advancing all three clinical programs as well as continuing to build out their medical device. Management is most likely going to take the month of April to prepare for their next steps in each of their clinical programs and should provide an update once everything is set. . .The streets becoming more bullish on the name as the stock has risen over 30% since its lows last week. . .keep RP.V on your radar screens and keep a very close eye on the story over the next few months."

BioTuesdays Publishing Co. (4/4/17)
"RepliCel Life Sciences Inc. reported statistically and clinically significant positive data from an interim analysis of its Phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin."

Zacks Small Cap Research (4/3/17)
"RepliCel Life Sciences Inc. announced the completion of the Phase 1 study as it successfully met its endpoints. The safety of RCH-01 was demonstrated through measurement of local and systemic tolerance that revealed no serious adverse events reported over the entire 60.5-month follow-up period. . .biopsies performed at 6, 12, and 24 months following injection did not show any evidence of the formation of tumor, granuloma, or foreign body formation. . .The results from the Phase 1 trial show that RCH-01 has a very clean safety profile."

Douglas Loe, Echelon Wealth Partners (3/28/17)
"We are increasing our RepliCel Life Sciences Inc. price target to $3.50 from $2.15. . .we believe our valuation is conservative when considering how solidly RepliCel has demonstrated functional improvement in at least two cell therapy markets, and with new Achilles tendon repair data serving as evidence for how NBDS could be relevant to other orthopedic/tendon repair markets like rotator cuff injury, or lateral epicondytis or patellar tendinitis, all with similar pathology to Achilles tendinosis. Our model solely values RCT-01 in Achilles tendinosis for now, since that is the only active tendon repair program in RepliCelís pipeline."

RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development.
read more >

More Expert Comments

Experts Following This Company

Douglas Loe, Analyst – Euro Pacific Canada
George Mack, Interviewer – BioDecade
Shane Matte BioTuesdays
Etienne Moshevich, Editor Alphastox.com
Colin Lee Novick, Managing Director – CJ PARTNERS
James West, Publisher and Editor Midas Letter

The information provided above is from analysts, newsletters, the company and other contributors.

RepliCel Life Sciences Inc. is a sponsor of Streetwise Reports.†The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Data announcements from 3 different clinical trials in Q1 2017
 
Biotech company focused on large aesthetic and sports injury markets
 
Small-cap biotech company expected to be generating revenue in 2018
catalyst Calendar
Q1
2017
Q1
2017
Q1
2017
Q2
2017
Next-phase clinical development plan announced
Q3
2017
1st functional prototypes of dermal injector
Q2
2018
CE-mark application for dermal injector
Q4
2018
Clinical data from pattern baldness trial (Japan)